Learn how we can help you get to the clinic. Fast.
Supporting a U.S. Biotech with DCS classification and product development of an NCE to rapidly achieve first-in-human
When a U.S. Biotech company wanted to determine the DCS (Developability Classification System) designation for their small molecule, they approached Quotient Sciences for a tailored formulation development program to quickly go from preclinical to first-in-human.
Let's discuss your program
Formulation development underpinned by biopharmaceutics & clinical knowledge
Quotient Sciences has more than 30 years of experience developing a breadth of formulations for small molecules and peptides, across a range of indications. With expertise in simple and complex dosage forms, we have formulated over 1,500 molecules. Our unique track record in clinical research, means we know what it takes to develop formulations across the full development pathway from preclinical to late stage.
Want to know more about our formulation capabilities?